A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Benralizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms ORCHID
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca KK
Most Recent Events
- 18 Jun 2025 Status changed from active, no longer recruiting to completed.
- 31 Aug 2023 Planned primary completion date changed from 13 Sep 2024 to 19 Aug 2024.
- 25 May 2023 Status changed from recruiting to active, no longer recruiting.